NASDAQ:RNA

Avidity Biosciences Stock Forecast, Price & News

$23.75
-0.21 (-0.88 %)
(As of 09/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$22.99
$24.93
50-Day Range
$18.16
$24.91
52-Week Range
$17.58
$36.04
Volume17,467 shs
Average Volume336,847 shs
Market Capitalization$894.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
30 days | 90 days | 365 days | Advanced Chart
Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Avidity Biosciences logo

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.

Headlines

Avidity Biosciences (NASDAQ:RNA) Trading 6.6% Higher
Avidity Biosciences (NASDAQ:RNA) Trading 6.6% Higher
September 17, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $23.92
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $23.92
September 14, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA)  Shares Down 6.8%
Avidity Biosciences (NASDAQ:RNA) Shares Down 6.8%
September 10, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Shares Up 5.6%
Avidity Biosciences (NASDAQ:RNA) Shares Up 5.6%
September 8, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $19.24
Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $19.24
September 7, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $22.84
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $22.84
September 1, 2021 |  americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume
Avidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume
August 30, 2021 |  americanbankingnews.com
Avidity Biosciences Inc.
Avidity Biosciences Inc.
August 25, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

177th out of 1,352 stocks

Pharmaceutical Preparations Industry

84th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Avidity Biosciences (NASDAQ:RNA) Frequently Asked Questions

Is Avidity Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Avidity Biosciences?

Wall Street analysts have given Avidity Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avidity Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Avidity Biosciences
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings data on Sunday, August, 8th. The biotechnology company reported ($0.70) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.01. Avidity Biosciences had a negative trailing twelve-month return on equity of 26.48% and a negative net margin of 846.95%.
View Avidity Biosciences' earnings history
.

What price target have analysts set for RNA?

4 Wall Street analysts have issued twelve-month price targets for Avidity Biosciences' shares. Their forecasts range from $36.00 to $50.00. On average, they anticipate Avidity Biosciences' share price to reach $43.00 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Avidity Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Avidity Biosciences' key executives?

Avidity Biosciences' management team includes the following people:
  • Dr. Troy Edward Wilson, Co-Founder & Chairman (Age 52, Pay $132k)
  • Ms. Sarah Boyce, Pres, CEO & Director (Age 49, Pay $823.09k)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 55, Pay $501.34k)
  • Dr. Jae B. Kim FACC, M.D., Chief Medical Officer (Age 51, Pay $340.64k)
  • Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 71)
  • Mr. Joseph Baroldi, Chief Operating Officer (Age 43)
  • Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 59)
  • Dr. Arthur A. Levin, Chief Scientific Officer (Age 67)
  • Dr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 63)

Who are some of Avidity Biosciences' key competitors?

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.02%), BlackRock Inc. (7.18%), Price T Rowe Associates Inc. MD (6.73%), Federated Hermes Inc. (5.23%), State Street Corp (3.57%) and Vanguard Group Inc. (3.38%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp.
View institutional ownership trends for Avidity Biosciences
.

Which institutional investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Goldman Sachs Group Inc., Millennium Management LLC, Morgan Stanley, Morgan Stanley, FMR LLC, Acuta Capital Partners LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Avidity Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Avidity Biosciences stock?

RNA stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., Federated Hermes Inc., Balyasny Asset Management LLC, Victory Capital Management Inc., Citigroup Inc., PDT Partners LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Avidity Biosciences
or or view top insider-buying stocks.

How do I buy shares of Avidity Biosciences?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $23.75.

How much money does Avidity Biosciences make?

Avidity Biosciences has a market capitalization of $894.66 million and generates $6.79 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 82 workers across the globe.

What is Avidity Biosciences' official website?

The official website for Avidity Biosciences is www.aviditybiosciences.com.

Where are Avidity Biosciences' headquarters?

Avidity Biosciences is headquartered at 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.